News | PET-CT | September 13, 2017

Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017

Trial assessed the impact of F-18 PET/CT on patient management in biochemically recurrent prostate cancer patients scheduled for salvage treatment with curative intent

Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017

September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALCON clinical trial of fluciclovine (18F) positron emission tomography/computed tomography (PET/CT) at the 2017 American Society for Radiation Oncology (ASTRO) annual meeting Sept. 24-27 in San Diego. The FALCON trial evaluated the impact of F-18 PET/CT on patient management in biochemically recurrent prostate cancer patients scheduled for salvage radiation therapy treatment with curative intent. Trial results will be presented by Eugene Teoh, M.D., Oxford University Hospitals NHS Trust, Oxford, U.K.

Blue Earth Diagnostics is also hosting an Industry-Expert Theater event, “A Novel Option for Biochemically Recurrent Prostate Cancer Localization,” with invited speaker Abhishek Solanki, M.D., assistant professor of radiation oncology, Loyola University School of Medicine, Chicago, which will be held on Tuesday, Sept. 26.

For more information: www.blueearthdiagnostics.com

Related Content

Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
Icon Launches New Clinical Trial Patient Engagement Platform
Technology | Patient Engagement | May 14, 2019
Icon plc announced the release of its web-based clinical trial patient engagement platform, to provide patients with...